Fusion Pharmaceuticals

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to becoming a leader in the field of targeted alpha therapy. Fusion's deep expertise in radiochemistry provides a replicable technology platform that transforms internalizing antibodies, which previously showed limited clinical efficacy, into highly potent cytotoxic drugs. Fusion can link the most effective isotopes with targeting antibodies, creating optimized agents for diagnostic imaging and radioimmunotherapy (precision medicine). After confirming tumor positivity with imaging agents, treatment with antibodies linked to therapeutic isotopes delivers a cytotoxic payload directly to cancer cells.Fusion’s lead product candidate, FPX-01, is a precision RIT and the result of this innovative approach. FPX-01 is designed to internalize into targeted cancer cells and deliver a lethal and highly localized radioactive payload. The precise targeting of this radiolabeled antibody induces selective and extremely potent cytotoxicity in tumor cells at relatively low doses of radiation.